 | Up a level |
Greto, D.; Van Hemelrijck, M.; Oppong, F.; Lievens, Y.; Ratosa, I.; Jereczek-Fossa, B.; Stellamans, K.; Peulen, H.; Verbeke, L.; Hemmatazad, H.; Ramella, S.; Braam, P.; Ivaldi, G.B.; Castro, P.; Shaukat, A.; Tsoutsou, P.; Olalla, S.C.; Sancho-Pardo, G.; Ost, P. and Guckenberger, M. (October 2023). 2140P Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort. Annals of oncology, 34, S1115. Elsevier 10.1016/j.annonc.2023.09.922
Kroeze, S.; Hemmatazad, H. (2023). OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations. Radiotherapy and oncology, S205-S206. Elsevier
Guckenberger, M.; Alongi, F.; Ricardi, U.; Scorsetti, M.; Balermpas, P.; Livi, L.; Lievens, Y.; Braam, P.; Jereczek- Fossa, B.A.; Stellamans, K.; Ratosa, I.; Peulen, H.; Widder, J.; Ramella, S.; Verbeke, L.; Dirix, P.; Khanfir, K.; Zilli, T.; Hemmatazad, H.; Jeene, P.; ... (2022). OC-0599 Factors associated with SBRT doses in oligometastatic disease: an EORTC/ESTRO OligoCare analysis. Radiotherapy and oncology, 170, S523-S524. Elsevier 10.1016/S0167-8140(22)02621-4
